Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CytRx Moves RNA Interference Into Separate Subsidiary

This article was originally published in The Pink Sheet Daily

Executive Summary

2006 Nobel Prize in Medicine recipient Craig Mello is a minority owner of RXi.

You may also be interested in...



CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition

Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.

CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition

Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.

Alnylam Seeks Deals As RNAi Interest Heats Up

Company looking to build on current deals with Merck and Novartis, COO says in interview with "The Pink Sheet" DAILY.

Topics

UsernamePublicRestriction

Register

PS064991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel